CytRx News

Canadian drugmaker AEterna Zentaris Inc. said Monday its enlarged prostate drug cetrorelix did not meet its main goal in a late-stage clinical study.

CytRx Corporation , a biopharmaceutical company, today announced favorable preliminary results from its Phase 2 STAR-1 registration clinical trial for tamibarotene in the treatment of acute promyelocytic leukemia in patients failing other treatments.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Shares of biopharmaceutical company CytRx Corp. rose in morning trading Wednesday after the Food and Drug Administration lifted a nearly two-year suspension on development of arimoclomol as a treatment for Lou Gehrig's disease.

CytRx Corporation , a biopharmaceutical company, is permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis , following the U.S. Food and Drug Administration's acceptance of a revised clinical trial protocol.

Main Category: Cancer / Oncology Also Included In: Clinical Trials / Drug Trials Article Date: 25 Nov 2009 CytRx Corporation , a biopharmaceutical company, today announced plans to initiate a multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a treatment for patients with advanced soft tissue sarcomas who have failed ...

Just as readers of BioMedReports were told on Monday, CytRx Corporation announced the first of two key news developments for the company on Tuesday.

The clouds of darkness that have been hanging over CytRx Corporation , may soon be cast aside.

CytRx Corporation , a biopharmaceutical company and a leader in molecular chaperone regulation technology, today announced that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a "significant strategy" in the future design of anti-aging pharmaceuticals.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

The Los Angeles Business Journal's index of the 200 largest local public companies rose sharply for the week ended Sept.

Sep 10, 2009 - CytRx Corporation , a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that it has been granted a key patent by the European Patent Office that covers through 2024 the use of its orally available molecular chaperone amplifier drug candidate arimoclomol for ...

CytRx Corporation , a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important ...

CytRx Corporation , a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important ...

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Aug 6, 2009 - CytRx Corporation , a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that it will receive a written correspondence from the U.S. Food and Drug Administration regarding its clinical program with arimoclomol as a treatment for amyotrophic lateral sclerosis ...

CytRx Corp. saw red ink on the bottom line in the second quarter, but, the loss was less than analysts estimated.

Aug 6, 2009 - CytRx Corporation , a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that it will receive a written correspondence from the U.S. Food and Drug Administration regarding its clinical program with arimoclomol as a treatment for amyotrophic lateral sclerosis ...

Main Category: Ovarian Cancer Also Included In: Cancer / Oncology Article Date: 29 Jul 2009 - 6:00 PDT CytRx Corporation , a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, announced that results demonstrating that its cancer drug candidate INNO-206 caused statistically significant ...

BIRMINGHAM, Ala.-- --MEDSEEK, the leading provider of eHealth portal solutions, announced today their existing client, Arizona's University Medical Center , has once again turned to the experts - LOS ANGELES-- --CytRx Corporation , a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, ...